Inhibition of upstream signals, as well as STAT3 using specific inhibitors or siRNA, significantly suppressed GSC sphere-formation, self-renewal activity, and tumor progression [45–47, 49], suggesting that inhibition of STAT3 signaling may be a therapeutic target for clinical applications associated with glioblastoma. This evidence concerns the gene STAT3 and neoplasm.